
Choisissez votre étiquette
affichée directement sur le flaconOstarine (MK-2866)
SARMs
- Expédié depuis l'Allemagne
Commande
- DHL avec suivi
- Emballage discret
4.6 sur 5 sur Trustpilot73 avis
Aussi recherché sous : Ostarin
En un coup d'œil
Ostarine (MK-2866) en chiffres
Les chiffres clés de notre lexique. Faites glisser le point le long de la courbe pour voir ce qui reste après une dose, par calcul.
Article complet du lexiqueHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~24 hours
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
approx.24hours
- Class
- SARMnon-steroidal
- Use
- Oraldaily
- Sizes
- 25 mg1 size in the shop
What studies show
All 2 sources in the lexicon- Dalton et al., Journal of Cachexia, Sarcopenia and Muscle, 2011
Phase 2 study of enobosarm against muscle wasting in cancer patients (opens in a new tab)
Dobs et al., The Lancet Oncology, 2013
Avis
Ce que disent les clients
Uniquement des commandes réelles qui contenaient Ostarine (MK-2866).
Tous les avisIl n'existe pas encore d'analyse de laboratoire pour Ostarine (MK-2866). Votez pourFaites-le tester vous-même, nous payons la moitiéToutes les analyses de laboratoire
Connaissances
Tout sur Ostarine (MK-2866)
Informations détaillées bientôt disponibles.
What is ostarine?
Ostarine, also enobosarm or MK-2866, is a non-steroidal modulator of the androgen receptor (SARM). It was developed against muscle wasting and is meant to act mainly in muscle and bone. It is not approved, the highest stage was phase 3.
What did the study in healthy older adults show?
120 men over 60 and postmenopausal women received placebo or one of four levels for 12 weeks. At the higher level fat-free mass rose by 1.3 kg more than on placebo, fat fell by about 0.6 kg and weight stayed the same. Stair climbing got faster and insulin resistance fell by 27.5 percent. Side effects were as frequent as on placebo.
And in cancer patients?
In a phase 2 trial with 159 cancer patients with weight loss median fat-free mass rose by 1.5 kg (lower level) and 1.0 kg (higher level), on placebo by 0.02 kg. According to the trial the most common serious events were not related to the drug.
What happens to blood lipids and hormones?
HDL cholesterol fell by 17 and 27 percent. The binding protein SHBG fell by 61 percent in men and 80 percent in women. Total testosterone fell in men as well. Free testosterone did not change significantly.
What did the highest study dose show?
A trial in 136 women with advanced breast cancer had two levels, the higher at 18 mg per day. After 24 weeks 29 to 32 percent had a clinical benefit (response or stable disease). Serious side effects caused by the drug occurred in 8 and 16 percent, mainly raised liver enzymes, too much calcium in the blood and fatigue.
Are trials still running?
Yes. As of 26 October 2026 a phase 2 trial with 239 participants is running that tests weight and body function on semaglutide. A first trial on this with 168 participants is completed. Two phase 3 trials in lung cancer ended in 2013.
Comparatifs
Comment il se compare
Produits associés
Produits similaires
MK-677 (Ibutamoren)
SARMs & brûleurs de graisse · SARMs SARMs
1 taille
LGD-4033 (Ligandrol)
SARMs & brûleurs de graisse · SARMs SARMs
1 taille
RAD-140 (Testolone)
SARMs & brûleurs de graisse · SARMs SARMs
1 taille
GW-501516 (Cardarine)
SARMs & brûleurs de graisse · SARMs SARMs
1 taille
Ostarine (MK-2866)

